MedTrace Logo

Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer

NCT06745219 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-12-20

No results posted yet for this study

Summary

Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer

Conditions

  • Thrombopenia
  • Cervical Cancer
  • Radiotherapy Side Effect
  • Chemotherapeutic Toxicity

Interventions

DRUG

herombopag

receive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Xiaofan Li, Dr · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-06-30
Completion
2025-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06745219 on ClinicalTrials.gov